Can You Get GLP-1 Without Diabetes? Insights into Usage and Access

Last reviewed: June 4, 2026

Last updated: June 4, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes — and for the weight-management products, having diabetes is not part of the labeled population at all. Wegovy and Zepbound are indicated for adults with obesity, or with overweight plus at least one weight-related condition, with no diabetes requirement. SURMOUNT-1, the pivotal tirzepatide obesity trial, explicitly excluded people with diabetes. The products that do require diabetes are the diabetes products: Ozempic, Mounjaro, Rybelsus and Ozempic tablets. Getting the product right is the entire access question.

What the Weight-Management Labels Require

Wegovy injection is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity.

Zepbound is indicated for chronic weight management on the same structural basis — obesity, or overweight plus at least one weight-related condition — and separately for moderate to severe obstructive sleep apnea in adults with obesity.

The pivotal trials used a body mass index of 30 kg/m² or greater for obesity, or 27 kg/m² or greater with at least one weight-related comorbid condition such as treated or untreated dyslipidemia or hypertension. Payers commonly mirror those thresholds, though payer criteria are set by the payer, not the FDA.

What Counts as a Weight-Related Condition

The commonly recognised ones include hypertension, dyslipidemia, prediabetes, obstructive sleep apnea, metabolic dysfunction-associated steatotic liver disease, cardiovascular disease, osteoarthritis and polycystic ovary syndrome.

Documentation matters more than presence. A condition recorded with a diagnosis code and a date in your chart carries weight in a coverage review; the same condition mentioned in passing does not. If you have one, make sure your prescriber records it explicitly.

Some of these map to their own approved indications. Obstructive sleep apnea in adults with obesity is a Zepbound indication in its own right; noncirrhotic MASH with moderate to advanced fibrosis is a Wegovy indication under accelerated approval; established cardiovascular disease supports Wegovy's cardiovascular indication.

The Evidence Base Was Built in People Without Diabetes

SURMOUNT-1 ran 72 weeks in 2,539 adults with obesity or overweight and excluded diabetes, reporting mean weight changes of −15.0%, −19.5% and −20.9% versus −3.1% with placebo. STEP 1 ran 68 weeks in 1,961 adults and reported −14.9% versus −2.4%.

The cardiovascular outcomes trial underlying Wegovy's cardiovascular indication also enrolled adults with overweight or obesity and established cardiovascular disease but without diabetes, reporting a primary composite endpoint of 6.5% versus 8% with placebo, hazard ratio 0.80.

In other words, the largest and most cited trials in this category were run specifically in people without diabetes. The idea that these are diabetes drugs being borrowed for weight loss describes an earlier era of the category.

What a Prescriber Assesses Beyond Eligibility

Labeled contraindications come first: a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and serious hypersensitivity to the drug or its excipients.

Then history that changes risk — pancreatitis, gallbladder disease, diabetic retinopathy, severe gastroparesis, current or planned pregnancy, and concurrent insulin or sulfonylurea use, which raises hypoglycemia risk even in someone whose glucose is otherwise well controlled.

Then the whole medication list, because both labels address the effect of delayed gastric emptying on concomitant oral drugs, with Wegovy specifically directing increased clinical or laboratory monitoring for narrow-therapeutic-index medications.

Coverage Is the Harder Barrier

Clinical eligibility and insurance coverage are different questions. Many employer plans exclude anti-obesity medications as a benefit category, and an exclusion cannot be overcome with clinical documentation because the plan never agreed to cover that class.

The most useful question to ask, in writing, is whether anti-obesity medications are an excluded benefit under your specific policy. That single answer tells you whether an appeal is worth pursuing or whether you are looking at a cash-pay route.

A cardiovascular or sleep apnea indication sometimes sits outside an anti-obesity exclusion because it is not a weight-reduction claim. If either applies to you, have it documented explicitly rather than implied.

What Not to Do

Do not misrepresent a diabetes diagnosis to obtain a diabetes product. Beyond the obvious problems, it puts you on a label whose dosage range and monitoring were designed for a different population and a different purpose.

Do not source medication outside the prescription system. The FDA has warned about counterfeit Ozempic, illegally marketed semaglutide and tirzepatide, and products falsely labeled "for research purposes" or "not for human consumption" sold to consumers with dosing instructions.

And do not treat a three-month plan as a plan. Randomised withdrawal trials across this class consistently show substantial regain after discontinuation, which is why the Wegovy indication itself includes maintaining weight reduction long term.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Do I need diabetes to be prescribed a GLP-1 medication?

Not for the weight-management products. Wegovy and Zepbound are indicated for adults with obesity, or with overweight plus at least one weight-related condition, with no diabetes requirement. SURMOUNT-1, the pivotal tirzepatide obesity trial, explicitly excluded people with diabetes. Ozempic, Mounjaro, Rybelsus and Ozempic tablets are the products that require a type 2 diabetes diagnosis.

What BMI is required?

The pivotal trials used a body mass index of 30 kg/m² or greater for obesity, or 27 kg/m² or greater with at least one weight-related comorbid condition such as treated or untreated dyslipidemia or hypertension. Insurance plans commonly mirror those thresholds in their prior authorization criteria, but payer criteria are set by the payer rather than by the FDA.

What conditions count as weight-related?

Commonly recognised ones include hypertension, dyslipidemia, prediabetes, obstructive sleep apnea, metabolic dysfunction-associated steatotic liver disease, cardiovascular disease, osteoarthritis and polycystic ovary syndrome. What matters most in practice is documentation: a condition recorded with a diagnosis code and date carries weight in a coverage review, whereas one mentioned informally does not.

Can I get Ozempic if I do not have diabetes?

Only off-label, and that creates no coverage obligation. Ozempic's three indications all require type 2 diabetes, and there is no BMI eligibility criterion anywhere in its label. If your concern is weight, Wegovy is the semaglutide product whose indications cover it. Misrepresenting a diabetes diagnosis to obtain a diabetes product is not a workaround.

Will insurance cover it without a diabetes diagnosis?

Often not, but the reason matters. Many employer plans exclude anti-obesity medications as a benefit category, which clinical documentation cannot overcome. Ask in writing whether that exclusion applies to your policy. A documented cardiovascular or obstructive sleep apnea indication sometimes falls outside such an exclusion because it is not a weight-reduction claim.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.